The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
Open accessAbstract
Background The skeleton and liver are frequently involved sites of metastasis in patients with metastatic renal cell carcinoma (RCC). Objective The purpose of this study was to analyze outcomes based on the presence of bone metastases (BM) and/or liver metastases (LM) in patients with RCC treated with targeted therapy. Design, Setting and Participants We conducted a review from the International Metastatic RCC Database Consortium (IMDC) of 2,027 patients with metastatic RCC. Outcome Measurements and Statistical Analysis We analyzed the impact of site of metastasis on overall survival (OS) and time-to-treatment failure (TTF). Statistical analyses were performed using multivariable Cox regression. Results and Limitations Presence of BM was 34% overall and when stratified by IMDC risk groups was 27%, 33%, and 43% in favorable, intermediate, and poor-risk groups, respectively (pitalic>0.001). Presence of LM was 19% overall and higher in the poor-risk patients (23%) compared to the favorable or intermediate-risk groups (17%) (p=0.003). When patients were classified into four groups based on the presence of BM and/or LM the hazard ratio (HR), adjusted for IMDC risk factors, was 1.4 (95% Confidence Interval (CI) 1.22–1.62) for BM, 1.42 (95% CI 1.17–1.73) for LM, and 1.82 (95% CI 1.47–2.26) for both BM and LM compared to other metastatic sites (pbold>0.0001). The prediction model performance for OS was significantly improved when BM and LM were added to the IMDC prognostic model (likelihood ratio test p<0.0001). Data in this analysis was collected retrospectively. Conclusions The presence of BM and LM in patients treated with targeted agents has a negative impact on survival. Patients with BM and/or LM may benefit from earlier inclusion on clinical trials of novel agents or combination-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Currently approved agents for the prevention of SREs in these patients include zoledronic acid, a potent bisphosphonate, and denosumab, a monoclonal antibody against the receptor activator of nuclear factor-kb ligand, a cytokine important in osteoclast differentiation, activation, and survival [13].”
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · cited 1×
“Given the significant intratumor heterogeneity in patients with metastatic RCC, the unique organ microenvironment of the liver may be selective for a more aggressive clinical phenotype [17,18].”
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Self-citationMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
Bianchi, M., Sun, M., Jeldres, C., Shariat, S. F., Trinh, Q.-D., Briganti, A., Tian, Z., Schmitges, J., Graefen, M., Perrotte, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr362 · Cited by 653
Mekhail, T. M., Abou-Jawde, R. M., BouMerhi, G., Malhi, S., Wood, L., Elson, P., & Bukowski, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.179 · Cited by 559
Self-citationNégrier, S., Escudier, B., Gomez, F., Douillard, J.-Y., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., & Lasset, C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf257 · Cited by 343
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Donskov, F., & von der Maase, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9594 · Cited by 299
Self-citation
Cited by
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationChoueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationTracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J. I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.057 · Cited by 829
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Self-citationKo, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 382
Self-citation
Metadata
- Authors
- McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S.-Y., Pal, S. K., Donskov, F., Tantravahi, S. K., Rini, B. I., Heng, D. Y. C., & Choueiri, T. K.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 65
- Issue
- 3
- Pages
- 577-584
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2069701490
- Cited by
- 253
- References
- 18
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. https://app.cochat.ai/papers/10.1016/j.eururo.2013.08.012
- The paper
- McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., Rha, S.-Y., Pal, S. K., Donskov, F., Tantravahi, S. K., Rini, B. I., Heng, D. Y. C., & Choueiri, T. K. (2014). Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology. https://doi.org/10.1016/j.eururo.2013.08.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.